Compare Appian Corp (APPN) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs Incyte Corporation — how do they compare? Appian Corp trades at $35.5 (market cap $2.54B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 9.7× Appian Corp's market cap, and Incyte Corporation is trading nearer its 52-week high, Appian Corp nearer its low. Which is the better fit depends on your goals.
| APPN | INCY | |
|---|---|---|
Market Cap | $2.54B | $24.54B |
Sector | Technology | Health |
52-Week High | $45.64 | $129.93 |
52-Week Low | $18.72 | $81.61 |
Enterprise Value | $2.67B | $20.04B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
